Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
Vergangene Veranstaltungen (max. 10)
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
ABO‐Blood Group Associates With Survival Outcomes in Patients With Metastatic Non‐Small Cell Lung Cancer Treated With Pembrolizumab MonotherapyIn: Thoracic Cancer, Jg. 16, 2025, Nr. 6, e70037DOI (Open Access)
-
BCL-B Promotes Lung Cancer Invasiveness by Direct Inhibition of BOKIn: Cells, Jg. 14, 2025, Nr. 4, 246DOI, Online Volltext (Open Access)
-
Early years, advanced disease : The unmet need in young adults with non-small cell lung cancerIn: European Journal of Cancer (EJC), Jg. 230, 2025, 116011DOI (Open Access)
-
Multimodale Therapiekonzepte beim lokal fortgeschrittenen NSCLCIn: TumorDiagnostik & Therapie, Jg. 46, 2025, Nr. 2, S. 113 – 116
-
Pathologic Complete Response Predicts Long-Term Survival Following Neoadjuvant Induction Chemotherapy and Chemo-Radiotherapy in Stage-III Non-Small Cell Lung CancerIn: Thoracic Cancer, Jg. 16, 2025, Nr. 22, e70183DOI (Open Access)
-
The effect of durvalumab consolidation after definitive radiochemotherapy for non-operable stage III non-small cell lung cancer on the dose effect relation for therapy related pulmonary infiltrates as a risk factor for pneumonitisIn: Translational Lung Cancer Research, Jg. 14, 2025, Nr. 6, S. 2074 – 2088DOI (Open Access)
-
[18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancerIn: European Journal of Nuclear Medicine and Molecular Imaging, 2025, in pressDOI (Open Access)
-
Theranostics with somatostatin receptor antagonists in SCLC : Correlation of 68Ga-SSO120 PET with immunohistochemistry and survivalIn: Theranostics, Jg. 14, 2024, Nr. 14, S. 5400 – 5412DOI, Online Volltext (Open Access)
-
PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab
Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging, July 11-14, 2020, Virtual,In: Journal of Nuclear Medicine (JNM). New York: Springer, Jg. 61, 2020, Nr. Suppl. 1, 243Online Volltext (Open Access) -
PERCIST-derived metabolic volume response predicts overall and progression-free survival in patients with malignant pleural mesothelioma treated with Pembrolizumab
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging. Berlin: Springer, Jg. 47, 2020, Nr. Supplement 1, S. S353DOI (Open Access) -
Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma
ESMO Virtual Congress 2020, 19.-21.09- und 16.-18.10.2020,In: Annals of Oncology. Amsterdam: Elsevier, Jg. 31, 2020, Nr. Suppl. 4, S. S1076 – S1077DOI (Open Access) -
Enhancing Lung Cancer Screening : A Comparative Evaluation of Predictive Models for Malignancy in Pulmonary Nodules
2025 World Conference on Lung Cancer, 6-9 September 2025, Barcelona, Spain,In: Journal of Thoracic Oncology. Amsterdam: Elsevier, Jg. 20, 2025, Nr. 10, Supplement 1, S. S666 – S667 -
Improved liquid biopsy sensitivity with large extracellular vesicle-associated DNAIn: Annals of Oncology. Amsterdam: Elsevier, Jg. 36, 2025, Nr. Suppl. 2, S. S281DOI (Open Access)